title: T-cell seeding: neonatal transfer of anti-myelin basic protein T-cell lines renders Fischer rats susceptible later in life to the active induction of experimental autoimmune encephalitis.
abstract: Fischer strain rats resist active induction of experimental autoimmune encephalomyelitis (EAE) following immunization with guinea-pig myelin basic protein (MBP) in complete Freund's adjuvant (CFA). Nevertheless, we now report that an encephalitogenic CD4(+) anti-MBP T-cell line could be developed from actively immunized Fischer rats. Adoptive transfer of the activated line mediated acute EAE in adult Fischer rats, but not in 1-day-old rats. Moreover, we found that both resting and activated anti-MBP T cells injected 1 day post-natally rendered these rats susceptible later in life to the active induction of EAE by immunization with MBP/CFA. The actively induced EAE manifested the accelerated onset of a secondary, memory-type response. Resting anti-MBP T cells injected even up to 2 weeks post-natally produced no clinical signs but seeded 50-100% of the recipients for an active encephalitogenic immune response to MBP. An earlier T-cell injection (1-2 days) produced a higher incidence and stronger response. The transferred resting T cells entered the neonatal spleen and thymus and proliferated there but did not change the total anti-MBP precursor number in adults. Splenocytes harvested from rats that were injected neonatally but not exposed to MBP in vivo proliferated strongly and produced significant amounts of interferon-gamma to MBP in vitro. Similar results were observed in rats injected with resting T-cell lines reactive to ovalbumin, suggesting that the neonatal injection of resting T cells specific for a self or for a foreign antigen can seed the immune system with the potential for an enhanced effector response to that antigen later in life.
authors.affiliation: Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. Volovitz@yahoo.com
authors.forename: Ilan
authors.initials: I
authors.lastname: Volovitz
authors.forename: Felix
authors.initials: F
authors.lastname: Mor
authors.forename: Arthur
authors.initials: A
authors.lastname: Machlenkin
authors.forename: Athur
authors.initials: A
authors.lastname: Machlenkin
authors.forename: Ofir
authors.initials: O
authors.lastname: Goldberger
authors.forename: Yotvat
authors.initials: Y
authors.lastname: Marmor
authors.forename: Lea
authors.initials: L
authors.lastname: Eisenbach
authors.forename: Irun R
authors.initials: IR
authors.lastname: Cohen
authors.forename: Irun
authors.initials: I
authors.lastname: Cohen
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D000831:Animals, Newborn; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D002460:Cell Line; D049109:Cell Proliferation; D004198:Disease Susceptibility; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D004676:Myelin Basic Protein / Q000276:immunology*; D010047:Ovalbumin / Q000276:immunology; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D013154:Spleen / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology
chemical_list: D004676:Myelin Basic Protein; D010047:Ovalbumin
references.citation: J Exp Med. 2005 Oct 3;202(7):907-12
references.pmid: 16203864
references.citation: Methods. 1996 Apr;9(2):233-47
references.pmid: 8812675
references.citation: J Clin Invest. 2004 Apr;113(8):1218-24
references.pmid: 15085201
references.citation: Clin Exp Neurol. 1985;21:226-31
references.pmid: 3843222
references.citation: J Exp Med. 1991 May 1;173(5):1039-46
references.pmid: 2022918
references.citation: J Immunol. 1992 Mar 15;148(6):1706-11
references.pmid: 1371785
references.citation: J Immunol. 1982 Sep;129(3):918-9
references.pmid: 6980923
references.citation: J Clin Invest. 1993 Nov;92(5):2199-206
references.pmid: 7693759
references.citation: J Immunol. 2008 Apr 1;180(7):4366-70
references.pmid: 18354156
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3874-9
references.pmid: 15001705
references.citation: Science. 2002 Oct 25;298(5594):850-4
references.pmid: 12242449
references.citation: Eur J Immunol. 1996 Aug;26(8):1866-74
references.pmid: 8765033
references.citation: Science. 1988 Jan 8;239(4836):181-3
references.pmid: 2447648
references.citation: Nat Immunol. 2004 May;5(5):469-71
references.pmid: 15116110
references.citation: Exp Clin Immunogenet. 1989;6(4):275-81
references.pmid: 2488687
references.citation: Nature. 1953 Oct 3;172(4379):603-6
references.pmid: 13099277
references.citation: Annu Rev Immunol. 2006;24:175-208
references.pmid: 16551247
references.citation: Immunity. 2003 Jan;18(1):131-40
references.pmid: 12530982
references.citation: Nature. 1981 Jul 2;292(5818):60-1
references.pmid: 6974307
references.citation: Eur J Immunol. 1999 Apr;29(4):1101-6
references.pmid: 10229076
references.citation: Autoimmun Rev. 2004 Jun;3(4):267-75
references.pmid: 15246022
references.citation: Vaccine. 2001 Dec 12;20(5-6):706-10
references.pmid: 11738733
references.citation: Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1185-90
references.pmid: 12525694
references.citation: J Autoimmun. 1999 Feb;12(1):13-25
references.pmid: 10028018
references.citation: J Immunol. 1995 Oct 1;155(7):3693-9
references.pmid: 7561070
references.citation: Nature. 1982 Nov 18;300(5889):262-4
references.pmid: 6183591
references.citation: Nat Med. 1999 Jul;5(7):843-7
references.pmid: 10395334
references.citation: Eur J Immunol. 1992 May;22(5):1193-8
references.pmid: 1374337
references.citation: Lab Invest. 1990 Feb;62(2):147-55
references.pmid: 1689408
references.citation: Immunity. 2001 May;14(5):547-60
references.pmid: 11371357
references.citation: Eur J Immunol. 1981 Mar;11(3):195-9
references.pmid: 6165588
references.citation: Science. 1993 Sep 10;261(5127):1451-4
references.pmid: 7690157
references.citation: J Immunol. 2005 Jul 1;175(1):69-81
references.pmid: 15972633